Assessing germline TP53 mutations in cancer patients: insights into Li-Fraumeni syndrome and genetic testing guidelines

Table 5 Clinical and morphological features of breast cancer in patients with mutations in the TP53 gene

	Sex	MN sites	Age (diagnosis)	Stage	HT	Grade	ER, % or score	PR, % or score	Ki67, %	Her2	office
P01	F	MPMN: 1) right breast	36	cT2N1M1, mts to the lungs, IV st	IUC	N/A	80–90%	80%	70	HER2 + (2 + , FISH +)	Lum B Her2 +
P01	F	2) left breast	38	cT2N3Mx	IUC	G3	0	0	90	HER2-	Triple-
P02	F	left breast	36	pT1cN0M0, IA st	IUC	G2	4	6	35	HER2 +	Lum B Her2 +
P03	F	right breast	35	pT1N0M0, IA st	IUC	G2	5	4	52	HER2-	Lum B Her2-
P04	F	left breast	28	cT2N0M0, IIa st	IUC	G3	0	0	70	HER2-	Triple-
P05	F	right breast	38	pT2N2M0, IIIA st	N/A	N/A	pos	pos	N/A	HER2-	Lum B Her2-
P06	F	MPMN: 1) right breast	47	pT1N0M0, IA st	IUC	G2	90%, 8	99%,8	23	HER2-	Lum B Her2-
P06	F	2) left breast	47	pTisN0M0 0 st	DC in situ	–-	–-	–-	–-	–-	–-
P07	F	left breast	33	cT2N0M0, IIA st	IUC	G2	8	8	50	HER2-(1 +)	Lum B Her2-
P08	F	MPMN: 1) Hodgkin's lymphoma IIIB	20	–-	–-	–-	–-	–-	–-	–-	–-
P08	F	2) left breast	29	T3N3M0, IIIC Art	IUC	G2	0	0	90	HER2-	Triple-
P09	F	right breast	49	pT2N1M0, IIB st	DC in situ with foci of invasion	N/A	0	0	30	HER2 + (3 +)	HR- Her2 +
P10	F	left breast	29	pT2N0M0, IIA st	IUC	G3	8	5	40	HER2 + (3 +)	Lum B Her2 +
P11	F	MPMN: 1) right breast	55	st4bN1fM0, IIIB st	IUC	G3	8	6	50	HER2-(1 +)	Lum B Her2-
P11	F	2) left breast	55	cT1bN0M0, IA st	IUC	G2	8	6	30	HER2 + (3 +)	Lum B Her2 +
P12	F	right breast	38	ycT4bN2fM0, IIIB st	IUC	G3	0	0	32	HER2 + (3 +)	HR- Her2 +
P13	F	left breast	66	cT2N0M0, IIA st	IUC	G2	0	0	N/A	HER2-	Triple-

Abbreviations: HT histological type, ER estrogen receptors, PR progesterone receptors, pos. positive receptor status, MBT molecular biological subtype, IUC invasive unspecified carcinoma, DC in situ – ductal carcinoma in situ, Lum – luminal subtype, HR- non-luminal subtype, Triple- triple negative subtype, N/A no data available

ISSN: 1897-4287